CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
04 mars 2024 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic...
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
28 févr. 2024 16h45 HE
|
CymaBay Therapeutics, Inc.
Gilead Sciences, Inc. has proposed to acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. U.S. FDA accepted seladelpar NDA for priority review, and seladelpar...
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 févr. 2024 16h05 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Therapeutics to Participate in Upcoming Investment Conferences
31 janv. 2024 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic...
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 janv. 2024 16h28 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
02 janv. 2024 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic...
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 déc. 2023 16h05 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 nov. 2023 16h15 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate Update
07 nov. 2023 16h04 HE
|
CymaBay Therapeutics, Inc.
Announced top-line results from RESPONSE Phase 3 study in PBC where seladelpar met the primary and two key secondary endpoints with high statistical significance. Seladelpar granted revised...
CymaBay Therapeutics to Present at Upcoming Investment Conferences
06 nov. 2023 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic...